Trial Profile
GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 11 Nov 2022
Price :
$35
*
At a glance
- Drugs GTB 3550 (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies; Mast Cell Leukemia; Myelodysplastic syndromes; Systemic mastocytosis
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors GT Biopharma
- 21 Mar 2022 Status changed from active, no longer recruiting to discontinued.
- 15 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 15 Sep 2021 According to a GT Biopharma media release, data from the study will be presented at the European Society for Medical Oncology (ESMO) Congress 2021. The abstract is currently available on the ESMO website at www.esmo.org. At the start of the mini-oral session the presentation will be available in the "Presentations" section of the Company's website at https://www.gtbiopharma.com.